Published by Global Banking & Finance Review®
Posted on February 25, 2026
2 min readLast updated: April 2, 2026
Add as preferred source on Google
Rovi posted a 3% rise in 2025 net profit to €140.4m as Okedi and heparins offset CDMO weakness; it proposes a €0.9594 dividend and sees 2026 revenue growing high single to low double digits. (marketscreener.com)
Feb 25 (Reuters) - Spanish drugmaker Laboratorios Farmaceuticos Rovi said on Wednesday its 2025 net profit rose 3% as higher sales of its schizophrenia drug Okedi and heparin products - as well as recognition of R&D aid - offset a decline in contract manufacturing revenue.
* Full-year net profit rose to 140.4 million euros, whileoperating revenue fell 3% to 743.5 million euros * CDMO revenue dropped 20% to 269.5 million euros onnegligible Moderna-related revenue and lower production volumesfor Moderna * Specialty pharmaceutical revenue increased 11% to 473.9million euros, driven by a 97% rise in Okedi sales and 7% in theheparin franchise, which includes low molecular weight heparins(LMWH) and other heparins * Gross profit rose 3% to 494.7 million euros, supported by36.3 million euros in R&D aid and lower LMWH raw material prices * Rovi will propose a dividend of 0.96 euros per share, apayout of around 35% * It expects 2026 operating revenue to grow by a highsingle-digit to low double-digit percentage(Reporting by Marta Serafinko in Gdansk; Editing by David Latona)
Rovi reported 2025 results: net profit up 3% to €140.4m as growth in Okedi and heparins offset weaker CDMO revenue. It also proposed a dividend and issued 2026 growth guidance. (marketscreener.com)
Okedi sales jumped 97% to €56.7m, while the heparin franchise rose 7% to €266.8m in 2025, driven by stronger partner orders. (europapress.es)
Rovi expects operating revenue to increase by a high single- to low double-digit percentage, with potential support from a pending Bristol Myers Squibb manufacturing deal. (marketscreener.com)
Explore more articles in the Finance category
